Palatin Technologies

285 articles with Palatin Technologies

• Palatin Presents On Pl8177 Oral Colon Delivery Formulation For Ulcerative Colitis At The 7Th CPC Symposium On Peptide Therapeutics

  10/17/2019

  Dr. Dodd was invited by symposium organizers to speak about the challenges of peptide drug development.

• Vyleesi™ Phase 3 Data To Be Presented At The 13th European Society Of Gynecology Congress

  10/16/2019

  Palatin Technologies, Inc. announced that data from two pivotal, double-blind placebo-controlled Phase 3 trials and the Exit Survey/Interview data on Vyleesi™ for hypoactive sexual desire disorder will be presented at the 13th European Society of Gynecology Conference in Vienna, Austria.

• Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year 2019 Results

  9/12/2019

  Palatin Technologies, Inc. (NYSE American: PTN), a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems, whose product candidates are targeted, receptor-specific therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, today announced results for its fourth quarter and fiscal year ended June 30, 2019.

• Palatin Technologies, Inc. to Report Fourth Quarter & Fiscal Year End 2019 Results; Teleconference and Webcast to be held on September 12, 2019

  9/11/2019

  Will announce its fourth quarter and fiscal year end 2019 operating results on Thursday, September 12, 2019 before the open of the U.S. financial markets.

• Palatin Technologies To Present At Canaccord Genuity's 39th Annual Growth Conference

  8/6/2019

  The conference will be held at the InterContinental Hotel in Boston, MA.

• Palatin Technologies Provides Mid-Calendar Year Corporate Update

  7/1/2019

  Palatin Technologies, Inc., a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, provided a mid-calendar year update on its corporate and clinical development programs.

• FDA Approves New Drug Application for Vyleesi™ (bremelanotide injection)

  6/21/2019

  Palatin Technologies, Inc. (NYSE American: PTN) announced today that the U.S. Food and Drug Administration (FDA) has granted marketing approval of AMAG Pharmaceuticals, Inc.'s New Drug Application (NDA) for Vyleesi

• Palatin Technologies Granted FDA Orphan Drug Designation -- PL-8177 for the Treatment of Non-Infectious Uveitis

  6/6/2019

  PL-8177 is a Melanocortin Receptor 1 Agonist

• Palatin Technologies, Inc. Reports Third Quarter Fiscal Year 2019 Results; Teleconference and Webcast to be held on May 9, 2019

  5/9/2019

  Palatin Technologies, Inc. announced results for its third quarter ended March 31, 2019.

• Palatin Technologies, Inc. to Report Third Quarter Fiscal Year 2019 Results; Teleconference and Webcast to be held on May 9, 2019

  5/3/2019

  Palatin Technologies, Inc. will announce its third quarter, fiscal year 2019 operating results on Thursday, May 9, 2019 before the open of the U.S. financial markets.

• Palatin Technologies Announces Positive Top Line Results of Oral Clinical Study of PL-8177 for Ulcerative Colitis and Other Inflammatory Bowel Diseases

  4/4/2019

  Study Met All Primary and Secondary Endpoints

• Palatin Technologies, Inc. Reports Second Fiscal Quarter 2019 Results and Provides Corporate Update

  2/12/2019

  Palatin Technologies, Inc. announced results for its second quarter ended December 31, 2018.

• Palatin Technologies, Inc. to Report Second Quarter Fiscal Year 2019 Results; Teleconference and Webcast to be held on February 12, 2019

  2/6/2019

  Palatin Technologies, Inc. will announce its second quarter fiscal year 2019 operating results on Tuesday, February 12, 2019 before the open of the U.S. financial markets.

• Palatin Technologies, Inc. Reports First Fiscal Quarter 2019 Results and Provides Corporate Update

  11/13/2018

  Teleconference and Webcast to be held on November 13, 2018

• Palatin Technologies, Inc. Announces First-in-Human Study Results of Subcutaneous Administration of PL-8177, An Investigational Melanocortin Receptor 1 Agonist

  11/8/2018

  Oral Formulation Clinical Data Currently Anticipated by Year End

• Palatin Technologies, Inc. to Report First Quarter Fiscal Year 2019 Results; Teleconference and Webcast to be held on November 13, 2018

  11/7/2018

  Palatin Technologies, Inc. will announce its first quarter fiscal year 2019 operating results on Tuesday, November 13, 2018 before the open of the U.S. financial markets.

• Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year 2018 Results

  9/13/2018

  Palatin Technologies, Inc. a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems for the treatment of diseases with significant unmet medical need and commercial potential

• Palatin Technologies, Inc. to Report Fourth Quarter and Fiscal Year End 2018 Results; Teleconference and Webcast to be held on September 13, 2018

  9/7/2018

  Palatin Technologies, Inc. will announce its fourth quarter and fiscal year end 2018 operating results on Thursday, September 13, 2018 before the open of the U.S. financial markets.

• Palatin Technologies Added to Russell 3000® Index

  6/25/2018

  Palatin Technologies, Inc. announced that it has been added to the Russell 3000® Index as part of the annual Russell U.S. Index reconstitution.

• Palatin Technologies Announces FDA Acceptance for Review of Bremelanotide NDA

  6/4/2018

  PDUFA Target Action Date March 23, 2019 Triggers Milestone Payment to Palatin of $20 Million